Pembrolizumab plus lenvatinib achieved a superior tumor response to axitinib-based regimens, whereas survival outcomes were comparable. Treatment selection should balance enhanced antitumor activity with differences in toxicity profiles.
No takes yet. Share an insight, caveat, or question.
Kobatake et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: